Drugs / MK-2640
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02269735 | Nov 2014 → Jul 2016 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269735 ↗ |
| Modality | Protein / enzyme biologic | “insulin analog” PMID 30125349 ↗ Sep 2018 |
| Route | Intravenous | “MK-2640 intravenous infusion administered to participant in a fasted state” NCT02269735 ↗ |